Xiao C Wan, MD
Allergy/Immunology · Menlo Park
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 1 carrier
- Office
- 1
Offices
1 location · University Healthcare Alliance · 334 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wan’s office at (650) 498-6500 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A135680 · Current
Licensed to practise in California · since 2015 · expires 2028-08-31 · University of Pittsburgh School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$204,505
Medicare paid this office $204,505 for 163 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, omalizumab, 5 mg | 14 | $78,504 | None |
| Return visit (30+ min) | 72 | $11,630 | $112 |
| New patient visit (45+ min) | 58 | $8,773 | $151 |
| Test for allergy using allergenic extract | 49 | $7,920 | $4 |
| Professional service for preparation and provision of 1 or more antigens | 16 | $6,851 | $15 |
See all 12 services
| Injection, omalizumab, 5 mg | 14 | $78,504 | None |
| Return visit (30+ min) | 72 | $11,630 | $112 |
| New patient visit (45+ min) | 58 | $8,773 | $151 |
| Test for allergy using allergenic extract | 49 | $7,920 | $4 |
| Professional service for preparation and provision of 1 or more antigens | 16 | $6,851 | $15 |
| Short return visit (20+ min) | 31 | $3,147 | $81 |
| Professional service for multiple injections of allergen | 11 | $2,139 | $11 |
| Injection of drug or substance under skin or into muscle | 21 | $1,785 | $14 |
| Test to measure expiratory airflow and volume | 36 | $1,580 | $27 |
| Test to measure the level of nitric oxide gas | 35 | $894 | $20 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 49 | $887 | $15 |
| Test for allergy using allergenic extract injected into skin | 18 | $786 | $9 |
Who their Medicare patients are
163 Original Medicare patients in 2024. Average age 74 · Women 65% · Health risk score 1.09. Above the middle of the specialty; the typical allergy/ immunology clinician is at 1.
Conditions among them: High blood pressure 48% · Coronary heart disease 25% · Cancer 21% · Diabetes 18% · COPD 14% · Atrial fibrillation 14% · Heart failure 12% · Depression 12% · Chronic kidney disease 11%.
The office billed $1,003,761, Medicare allowed $260,596 and paid $204,505; for 9,300 services of 28 kinds; $151,292 of it was for drugs given in the office and $53,214 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 163 | 9,300 | 74 | 1.09 | $1,003,761 | $204,505 |
| 2023 | 175 | 9,609 | 73 | 0.99 | $949,522 | $203,498 |
| 2022 | 281 | 9,044 | 72 | 0.92 | $713,946 | $152,115 |
| 2021 | 213 | 7,032 | 72 | 0.89 | $330,394 | $95,807 |
| 2020 | 181 | 5,070 | 72 | 0.92 | $184,265 | $69,748 |
| 2019 | 172 | 4,685 | 73 | 0.80 | $156,861 | $61,162 |
| 2018 | 216 | 5,865 | 73 | 0.91 | $185,748 | $74,174 |
| 2017 | 32 | 435 | 71 | 0.78 | $15,100 | $6,779 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Injection, omalizumab, 5 mg | 13 | $60,534 | None |
| Return visit (30+ min) | 85 | $13,330 | $111 |
| Test for allergy using allergenic extract | 51 | $9,556 | $4 |
| New patient visit (45+ min) | 55 | $8,190 | $149 |
| Professional service for preparation and provision of 1 or more antigens | 16 | $7,092 | $16 |
| Short return visit (20+ min) | 29 | $3,156 | $81 |
| Long return visit (40+ min) | 18 | $3,054 | $161 |
| New patient visit (60+ min) | 11 | $2,236 | $203 |
| Professional service for multiple injections of allergen | 12 | $2,020 | $11 |
| Test for allergy using allergenic extract injected into skin | 23 | $1,485 | $8 |
| Injection of drug or substance under skin or into muscle | 23 | $1,432 | $14 |
| Test to measure expiratory airflow and volume | 23 | $849 | $27 |
| Test to measure the level of nitric oxide gas | 15 | $343 | $20 |
2022: 12 services
| Injection, omalizumab, 5 mg | 12 | $52,798 | None |
| Return visit (30+ min) | 175 | $24,867 | $90 |
| Professional service for preparation and provision of 1 or more antigens | 48 | $11,913 | $14 |
| Test for allergy using allergenic extract | 59 | $11,761 | $3 |
| New patient visit (45+ min) | 59 | $7,806 | $132 |
| Professional service for multiple injections of allergen | 65 | $5,393 | $9 |
| Test to measure expiratory airflow and volume | 88 | $2,454 | $18 |
| Short return visit (20+ min) | 29 | $2,148 | $69 |
| Test for allergy using allergenic extract injected into skin | 38 | $1,635 | $8 |
| Test to measure the level of nitric oxide gas | 59 | $1,133 | $13 |
| Professional service for single injection of allergen | 14 | $1,095 | $8 |
| Injection of drug or substance under skin or into muscle | 21 | $940 | $13 |
2021: 9 services
| Return visit (30+ min) | 143 | $29,606 | $107 |
| Test for allergy using allergenic extract | 57 | $16,206 | $4 |
| Professional service for preparation and provision of 1 or more antigens | 53 | $12,608 | $15 |
| New patient visit (45+ min) | 63 | $8,388 | $133 |
| Professional service for multiple injections of allergen | 59 | $7,505 | $10 |
| Test to measure expiratory airflow and volume | 114 | $6,462 | $27 |
| Short return visit (20+ min) | 56 | $5,741 | $78 |
| Test to measure the level of nitric oxide gas | 75 | $2,530 | $19 |
| Test for allergy using allergenic extract injected into skin | 52 | $2,481 | $8 |
2020: 9 services
| Return visit (30+ min) | 117 | $17,732 | $87 |
| Professional service for preparation and provision of 1 or more antigens | 51 | $13,530 | $14 |
| Test for allergy using allergenic extract | 31 | $10,054 | $4 |
| Professional service for multiple injections of allergen | 60 | $7,821 | $9 |
| New patient visit (45+ min) | 41 | $5,881 | $143 |
| Short return visit (20+ min) | 66 | $5,287 | $59 |
| Test to measure expiratory airflow and volume | 76 | $3,696 | $32 |
| Test for allergy using allergenic extract injected into skin | 27 | $1,464 | $8 |
| Test to measure the level of nitric oxide gas | 41 | $963 | $19 |
2019: 9 services
| Professional service for preparation and provision of 1 or more antigens | 56 | $14,242 | $14 |
| Return visit (30+ min) | 69 | $8,789 | $91 |
| Test for allergy using allergenic extract | 29 | $8,276 | $4 |
| Short return visit (20+ min) | 90 | $7,164 | $56 |
| Professional service for multiple injections of allergen | 58 | $7,083 | $9 |
| Test to measure expiratory airflow and volume | 92 | $5,250 | $31 |
| New patient visit (45+ min) | 33 | $4,390 | $133 |
| Test for allergy using allergenic extract injected into skin | 26 | $1,353 | $8 |
| Test to measure the level of nitric oxide gas | 43 | $1,125 | $19 |
2018: 12 services
| Test for allergy using allergenic extract | 53 | $17,128 | $5 |
| Return visit (30+ min) | 118 | $14,609 | $84 |
| Professional service for preparation and provision of 1 or more antigens | 34 | $8,084 | $13 |
| New patient visit (45+ min) | 54 | $6,913 | $128 |
| Test to measure expiratory airflow and volume | 142 | $6,801 | $30 |
| Short return visit (20+ min) | 84 | $5,882 | $55 |
| Professional service for multiple injections of allergen | 55 | $4,868 | $9 |
| Test for allergy using allergenic extract injected into skin | 42 | $2,180 | $7 |
| Test for allergy using ingested items, initial 2 hours | 12 | $1,372 | $106 |
| Test to measure the level of nitric oxide gas | 50 | $1,353 | $19 |
| New patient visit (30+ min) | 13 | $992 | $76 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 15 | $908 | $57 |
2017: 3 services
| Return visit (30+ min) | 15 | $1,487 | $87 |
| Test to measure expiratory airflow and volume | 21 | $774 | $32 |
| Test to measure the level of nitric oxide gas | 13 | $233 | $18 |
Drugs they prescribed that Part D paid
$328,087
Pharmacies billed $328,087 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 505) in 2024. At or below the middle of the specialty; the typical allergy/ immunology clinician is at 0%.
285 generic and 220 brand-name prescriptions · $328,087 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | None | 27 | $106,219 | $3,934 |
| Gamunex-C | Immune globulin | 16 | $40,472 | $2,530 |
| Trelegy Ellipta | None | 43 | $29,406 | $684 |
| Alvesco | None | 11 | $9,400 | $855 |
| Breo Ellipta | None | 13 | $5,082 | $391 |
See all 12 drugs
| Dupixent | None | 27 | $106,219 | $3,934 |
| Gamunex-C | Immune globulin | 16 | $40,472 | $2,530 |
| Trelegy Ellipta | None | 43 | $29,406 | $684 |
| Alvesco | None | 11 | $9,400 | $855 |
| Breo Ellipta | None | 13 | $5,082 | $391 |
| Wixela Inhub | None | 28 | $2,355 | $84 |
| Epinephrine | None | 14 | $1,493 | $107 |
| Azelastine-Fluticasone | None | 14 | $1,428 | $102 |
| Ipratropium | None | 37 | $1,401 | $38 |
| Azelastine | None | 49 | $1,292 | $26 |
| Albuterol Sulfate Hfa | None | 30 | $997 | $33 |
| Montelukast | None | 55 | $750 | $14 |
Year by year
| 2024 | 505 | 160 | 0% (0) | 44% | $328,087 |
| 2023 | 646 | 199 | 0% (0) | None | $489,968 |
| 2022 | 1,183 | 233 | None | None | $986,295 |
| 2021 | 1,046 | 181 | None | 37% | $730,386 |
| 2020 | 956 | 179 | None | 37% | $334,773 |
| 2019 | 713 | 152 | None | 37% | $208,621 |
| 2018 | 624 | 170 | None | 36% | $164,823 |
| 2017 | 42 | 22 | 0% (0) | 52% | $42,321 |
| 2016 | 40 | 12 | 0% (0) | None | $394,655 |
| 2015 | 285 | 59 | None | 17% | $19,656 |
| 2014 | 456 | 59 | 4% (18) | 18% | $28,180 |
| 2013 | 262 | 60 | 7% (17) | None | $13,885 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Dupixent | 18 | $66,153 | $3,675 |
| Trelegy Ellipta | 27 | $23,768 | $880 |
| Advair Hfa | 19 | $15,389 | $810 |
| Symbicort | 32 | $14,965 | $468 |
| Breo Ellipta | 19 | $9,787 | $515 |
| Advair Diskus | 15 | $6,465 | $431 |
| Flovent Hfa | 13 | $4,873 | $375 |
| Epinephrine | 22 | $4,570 | $208 |
| Azelastine | 84 | $2,856 | $34 |
| Mometasone Furoate | 11 | $1,837 | $167 |
| Ipratropium | 46 | $1,419 | $31 |
| Montelukast | 74 | $1,033 | $14 |
| Albuterol Sulfate Hfa | 35 | $916 | $26 |
| Fluticasone Propionate | 36 | $633 | $18 |
| Famotidine | 13 | $135 | $10 |
| Omeprazole | 14 | $90 | $6 |
| Prednisone | 13 | $48 | $4 |
2022: 22 drugs
| Takhzyro | 11 | $550,431 | $50,039 |
| Trelegy Ellipta | 93 | $77,700 | $835 |
| Breo Ellipta | 99 | $47,344 | $478 |
| Dupixent | 13 | $44,213 | $3,401 |
| Symbicort | 43 | $25,591 | $595 |
| Spiriva Respimat | 22 | $18,688 | $849 |
| Advair Hfa | 21 | $16,056 | $765 |
| Flovent Hfa | 38 | $13,296 | $350 |
| Serevent Diskus | 12 | $9,055 | $755 |
| Wixela Inhub | 15 | $7,168 | $478 |
| Advair Diskus | 13 | $6,881 | $529 |
| Azelastine | 168 | $6,775 | $40 |
| Ipratropium | 63 | $3,360 | $53 |
| Albuterol Sulfate Hfa | 68 | $3,228 | $47 |
| Montelukast | 136 | $2,584 | $19 |
| Epinephrine | 12 | $2,270 | $189 |
| Levocetirizine Dihydrochloride | 16 | $1,125 | $70 |
| Ventolin Hfa | 11 | $977 | $89 |
| Fluticasone Propionate | 35 | $564 | $16 |
| Amoxicillin-Clavulanate Potass | 22 | $301 | $14 |
| Hydroxyzine | 19 | $199 | $10 |
| Prednisone | 41 | $136 | $3 |
2021: 22 drugs
| Firazyr | None | 11 | $388,483 | $35,317 |
| Hizentra | Immune globulin | 13 | $68,795 | $5,292 |
| Dupixent | None | 14 | $45,227 | $3,231 |
| Symbicort | None | 45 | $34,024 | $756 |
| Breo Ellipta | None | 63 | $30,369 | $482 |
| Trelegy Ellipta | None | 24 | $24,911 | $1,038 |
| Spiriva Respimat | None | 22 | $20,284 | $922 |
| Advair Diskus | None | 30 | $17,478 | $583 |
| Flovent Hfa | None | 35 | $12,956 | $370 |
| Advair Hfa | None | 13 | $9,655 | $743 |
| Serevent Diskus | None | 11 | $9,230 | $839 |
| Wixela Inhub | None | 21 | $8,904 | $424 |
| Azelastine | None | 138 | $6,294 | $46 |
| Ipratropium | None | 67 | $3,900 | $58 |
| Montelukast | None | 181 | $3,018 | $17 |
| Albuterol Sulfate Hfa | None | 49 | $2,553 | $52 |
| Fluticasone Propionate | None | 28 | $567 | $20 |
| Omeprazole | None | 24 | $510 | $21 |
| Clarithromycin | None | 11 | $457 | $42 |
| Amoxicillin-Clavulanate Potass | None | 16 | $262 | $16 |
| Hydroxyzine | None | 18 | $246 | $14 |
| Prednisone | None | 49 | $142 | $3 |
2020: 19 drugs
| Hizentra | Immune globulin | 14 | $80,573 | $5,755 |
| Symbicort | None | 56 | $36,986 | $660 |
| Dupixent | None | 11 | $34,501 | $3,136 |
| Breo Ellipta | None | 37 | $22,402 | $605 |
| Spiriva Respimat | None | 24 | $17,383 | $724 |
| Advair Diskus | None | 23 | $13,980 | $608 |
| Wixela Inhub | None | 21 | $7,484 | $356 |
| Azelastine | None | 139 | $6,688 | $48 |
| Flovent Hfa | None | 16 | $5,616 | $351 |
| Qvar Redihaler | None | 11 | $4,605 | $419 |
| Albuterol Sulfate Hfa | None | 45 | $3,127 | $69 |
| Ipratropium | None | 36 | $2,872 | $80 |
| Montelukast | None | 154 | $2,258 | $15 |
| Levalbuterol Tartrate Hfa | None | 18 | $1,301 | $72 |
| Hydroxyzine | None | 46 | $816 | $18 |
| Amoxicillin-Clavulanate Potass | None | 25 | $748 | $30 |
| Fluticasone Propionate | None | 24 | $734 | $31 |
| Omeprazole | None | 12 | $247 | $21 |
| Prednisone | None | 54 | $210 | $4 |
2019: 19 drugs
| Hizentra | Immune globulin | 13 | $74,057 | $5,697 |
| Symbicort | None | 62 | $33,074 | $533 |
| Advair Diskus | None | 17 | $10,665 | $627 |
| Breo Ellipta | None | 14 | $10,356 | $740 |
| Azelastine | None | 80 | $3,629 | $45 |
| Wixela Inhub | None | 11 | $3,542 | $322 |
| Flovent Diskus | None | 12 | $3,041 | $253 |
| Ipratropium | None | 23 | $1,926 | $84 |
| Montelukast | None | 111 | $1,742 | $16 |
| Ventolin Hfa | None | 21 | $1,621 | $77 |
| Levalbuterol Tartrate Hfa | None | 16 | $1,250 | $78 |
| Albuterol Sulfate Hfa | None | 14 | $1,117 | $80 |
| Clarithromycin | None | 13 | $502 | $39 |
| Fluticasone Propionate | None | 28 | $349 | $12 |
| Hydroxyzine | None | 19 | $332 | $17 |
| Amoxicillin-Clavulanate Potass | None | 21 | $319 | $15 |
| Levothyroxine | None | 16 | $218 | $14 |
| Mupirocin | None | 13 | $135 | $10 |
| Prednisone | None | 29 | $95 | $3 |
2018: 17 drugs
| Hizentra | Immune globulin | 13 | $73,496 | $5,654 |
| Symbicort | None | 34 | $18,452 | $543 |
| Advair Diskus | None | 12 | $9,352 | $779 |
| Azelastine | None | 88 | $4,599 | $52 |
| Flovent Hfa | None | 14 | $4,008 | $286 |
| Olopatadine | None | 24 | $2,475 | $103 |
| Ventolin Hfa | None | 30 | $2,240 | $75 |
| Proair Hfa | None | 15 | $1,700 | $113 |
| Ipratropium | None | 21 | $1,582 | $75 |
| Montelukast | None | 70 | $1,316 | $19 |
| Levalbuterol Tartrate Hfa | None | 11 | $730 | $66 |
| Hydroxyzine | None | 15 | $291 | $19 |
| Fluticasone Propionate | None | 23 | $286 | $12 |
| Amoxicillin-Clavulanate Potass | None | 22 | $264 | $12 |
| Prednisone | None | 39 | $149 | $4 |
| Mupirocin | None | 13 | $136 | $10 |
| Azithromycin | None | 13 | $91 | $7 |
2015: 6 drugs
| Isosorbide Dinitrate | 12 | $736 | $61 |
| Atorvastatin | 20 | $525 | $26 |
| Insulin | 12 | $301 | $25 |
| Amlodipine Besylate | 26 | $169 | $6 |
| Simvastatin | 18 | $126 | $7 |
| Lisinopril | 11 | $92 | $8 |
2014: 11 drugs
| Lantus | 15 | $4,159 | $277 |
| Atorvastatin | 22 | $781 | $35 |
| Metoprolol | 14 | $734 | $52 |
| Labetalol | 13 | $663 | $51 |
| Losartan | 11 | $467 | $42 |
| Simvastatin | 22 | $365 | $17 |
| Amlodipine Besylate | 30 | $342 | $11 |
| Glipizide | 11 | $148 | $13 |
| Tramadol | 12 | $116 | $10 |
| Lisinopril | 12 | $115 | $10 |
| Hydrochlorothiazide | 14 | $80 | $6 |
2013: 2 drugs
| Amlodipine Besylate | 12 | $174 | $15 |
| Tramadol | 13 | $133 | $10 |
Money from drug and device companies
$46 in 2025
| 2025 | 1 | 2 | None | $46 |
| 2024 | 4 | 6 | None | $307 |
| 2023 | 1 | 3 | None | $44 |
| 2022 | 2 | 3 | None | $46 |
| 2021 | 3 | 6 | None | $102 |
| 2020 | 4 | 12 | None | $375 |
| 2019 | 4 | 5 | $25 | $211 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Rhapsido | $46 | 2 payments
|
See all 2 published payments
| Novartis Pharmaceuticals | Meals · 2025-12-09 | Rhapsido | $24 |
| Novartis Pharmaceuticals | Meals · 2025-12-09 | Rhapsido | $22 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $307
| AstraZeneca Pharmaceuticals LP | Tezspire | $125 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $123 | 2 payments
|
| Genzyme | Dupixent | $34 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Cuvitru | $25 | 1 payment
|
2023: $44
| Pfizer | Cibinqo | $44 | 3 payments
|
2022: $46
| GlaxoSmithKline | Nucala | $25 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $21 | 1 payment
|
2021: $102
| GlaxoSmithKline | Nucala | $73 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $16 | 1 payment
|
| Horizon Therapeutics plc | Actimmune | $13 | 1 payment
|
2020: $375
| GlaxoSmithKline | Nucala | $129 | 7 payments
|
| Genzyme | Dupixent | $125 | 1 payment
|
| ALK-Abello | Odactra | $75 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Breztri Aerosphere | $45 | 3 payments
|
2019: $211
| ALK-Abello | Odactra | $125 | 1 payment
|
| Genzyme | Dupixent | $45 | 2 payments
|
| CSL Behring | Haegarda | $25 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $15 | 1 payment
|
Professional record
- NPI
- 1295099042
- Licence
- CA A135680California A135680: Current · expires 2028-08-31
- Trained
- University of Pittsburgh School of Medicine, 2012
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207K00000X (207K00000X); Internal medicine (207R00000X)
- Mailing address
- 4050 Moorpark Ave, San Jose, CA, 95117
- NPI first listed
- 2012-06-26
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 4050 Moorpark Ave, San Jose, CA, 95117